Back to search results

Lysergic Acid Diethylamide (LSD) in Palliative Care

Abroad (travel likely)RecruitingPHASE2

Conditions

Palliative Care · Pain · Anxiety · Depression · Demoralization · Psychological Distress · Quality of Life · Caregiver Burden · Fear of Death · Existential Distress

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • University Hospital Basel, Division of Clinical Pharmacology and Toxicology, Basel, Switzerland

    Contact: Study coordinator (Yasmin Schmid, PD Dr. med.) · yasmin.schmid@usb.ch · +41 61 328 68 47
    Contact: Study coordinator (Melani Zupari, MSc) · melani.zuparic@usb.ch · +41 61 328 77 42
    Contact: Principal Investigator (Yasmin Schmid, PD Dr. med.)
    Matthias Liechti, Prof. Dr. med. (Sub-investigator)

  • University Hospital Geneva, Palliative medicine department, Collonge-Bellerive, Switzerland

    Contact: Study coordinator (Michael Ljuslin, Dr. med.) · michael.ljuslin@hug.ch · +41 79 553 87 92

  • Spital Uster AG, Division of Internal Medicine, Uster, Switzerland

    Contact: Study coordinator (Sivan Schipper, MD) · sivan.schipper@spitaluster.ch · +41 44 911 12 91

  • University Hospital Zurich, Clinic for Radio-Oncology, Competence Centre Palliative Care, Zurich, Switzerland

    Contact: Study coordinator (David Blum, Prof Dr med) · david.blum@usz.ch · +41 44 255 37 42
Study leads

  • Yasmin Schmid, PD Dr. med.

    Principal Investigator

    University Hospital, Basel, Switzerland

View source on ClinicalTrials.gov(opens in a new tab)